AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17437361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study 16340523 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckle (SB) surgery
Number of subjects: 150
Study 16340523 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 150
Study 12022008 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoscopy performed immediately after the orthoptic examination
Number of subjects: 32
Study 12022008 — intervention group
Group type: COMPARATOR
Intervention: Retinoscopy performed during an additional visit
Number of subjects: 32
Study 9640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory assistance
Number of subjects: 12
Study 9640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation and two levels of pressure assistance
Number of subjects: 12
Study 9640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Different waveforms of flow or pressure from the ventilators
Number of subjects: 12
Study 8043290 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group II)
Number of subjects: 281
Study 8043290 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia (Group I)
Number of subjects: 281
Study 3177528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon brush
Number of subjects: 0
Study 3177528 — intervention group
Group type: COMPARATOR
Intervention: Cotton‐tipped swab and wooden spatula
Number of subjects: 0
Study 29624630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (tooth whitening with photoactivated gel)
Number of subjects: 60
Study 29624630 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 28114928 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing + photodynamic therapy (PDT) + oral hygiene orientation (OHO)
Number of subjects: 64
Study 28114928 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene orientation (OHO) + supragingival treatment + simulation of using photodynamic therapy (PDT)
Number of subjects: 64
Study 25092036 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 42
Study 25092036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23245469 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM program (high adherence)
Number of subjects: 1477
Study 23245469 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM program (low adherence)
Number of subjects: 1477
Study 23245469 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 1477
Study 21985296 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of core elements of the Chronic Care Model via a specially trained Chronic Care Coach
Number of subjects: 352
Study 21985296 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study 17673699 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made device
Number of subjects: 35
Study 17673699 — intervention group
Group type: COMPARATOR
Intervention: Thermoplastic device
Number of subjects: 35
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Basal Insulin
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Basal and Prandial Insulin
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Grades 2-4)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Grades 3-4)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (<45 years)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Older patients (>=45 years)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight (BMI <25 kg/m2)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Overweight (BMI >=25 kg/m2)
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <7%
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: HbA1c >=7%
Number of subjects: 5063
Study 17070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet autoantibody-positive patients
Number of subjects: 5063
Study 17070446 — intervention group
Group type: COMPARATOR
Intervention: Islet autoantibody-negative patients
Number of subjects: 5063
Study 14624050 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 300
Study 14624050 — intervention group
Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 300
Study 11115311 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 22
Study 11115311 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study 9200390 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (TPA)
Number of subjects: 0
Study 9200390 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with subcutaneously administered heparin
Number of subjects: 0
Study 9200390 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with intravenously administered heparin
Number of subjects: 0
Study 1410141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg daily for 8 weeks, followed by 4 weeks of continuation)
Number of subjects: 40
Study 1410141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks followed by 4 weeks of continuation)
Number of subjects: 40
Study 3933455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 15.6% branched-chain amino acids
Number of subjects: 15
Study 3933455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solutions with 50% branched-chain amino acids
Number of subjects: 15
Study 3933455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solutions with 100% branched-chain amino acids
Number of subjects: 15
Study 3933455 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid formula
Number of subjects: 15
Study 30862454 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the QUIP-RS
Number of subjects: 280
Study 30862454 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIP-RS total score
Number of subjects: 280
Study 30829275 — intervention group
Group type: EXPERIMENTAL
Intervention: Games and story therapy along with motivational intervention (Group B)
Number of subjects: 82
Study 30829275 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading and writing therapy along with motivational intervention (Group C)
Number of subjects: 82
Study 30829275 — intervention group
Group type: COMPARATOR
Intervention: Motivational intervention alone (Group A)
Number of subjects: 82
Study 30829275 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 82
Study 26786576 — intervention group
Group type: COMPARATOR
Intervention: PLBO/WHEY
Number of subjects: 22
Study 26786576 — intervention group
Group type: COMPARATOR
Intervention: VILD/CTRL
Number of subjects: 22
Study 26786576 — intervention group
Group type: EXPERIMENTAL
Intervention: VILD/WHEY
Number of subjects: 22
Study 24770617 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG+rituximab
Number of subjects: 15
Study 24770617 — intervention group
Group type: COMPARATOR
Intervention: IVIG+placebo
Number of subjects: 15
Study 22472994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 30 mg twice daily
Number of subjects: 10
Study 22472994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 100 mg twice daily
Number of subjects: 10
Study 22472994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 10
Study 22472994 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no gemfibrozil)
Number of subjects: 10
Study 19810670 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner‐centered simulation intervention with trained actors as standardized family members, including a formal training session and a 60-minute practice session
Number of subjects: 100
Study 19810670 — intervention group
Group type: COMPARATOR
Intervention: Control group with current standard education only
Number of subjects: 100
Study 19810670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study 17956562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 20
Study 17956562 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 20
Study 16195165 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (FMT)
Number of subjects: 26
Study 16195165 — intervention group
Group type: COMPARATOR
Intervention: Control group (FMC)
Number of subjects: 26
Study 11897925 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg telmisartan + 12.5 mg HCTZ
Number of subjects: 327
Study 11897925 — intervention group
Group type: COMPARATOR
Intervention: 40 mg telmisartan
Number of subjects: 327
Study 10360855 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% arginine hydrochloride, 30 g over 15 min)
Number of subjects: 20
Study 10360855 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 8588693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (1.2 and 3.6 mg per nasal cavity)
Number of subjects: 0
Study 8588693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (7.2 mg)
Number of subjects: 0
Study 8588693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1790038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (21% of total calories from fat)
Number of subjects: 253
Study 1790038 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (38% of total calories from fat)
Number of subjects: 253
Study 1790038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 253
Study 1790038 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 253
Study 7148839 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline pharmacokinetic monitoring service
Number of subjects: 60
Study 7148839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without pharmacokinetic monitoring)
Number of subjects: 60
Study 7148839 — intervention group
Group type: COMPARATOR
Intervention: Control group (with steady-state concentrations drawn)
Number of subjects: 60
Study 7148839 — intervention group
Group type: COMPARATOR
Intervention: Control group (without steady-state concentrations drawn)
Number of subjects: 60
Study 7148839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study 30408199 — intervention group
Group type: COMPARATOR
Intervention: CVD screening plus incentive double points (Group 3)
Number of subjects: 570
Study 30408199 — intervention group
Group type: COMPARATOR
Intervention: CVD screening with routine points (Group 2)
Number of subjects: 570
Study 30408199 — intervention group
Group type: COMPARATOR
Intervention: Routine points (Group 1, control)
Number of subjects: 570
Study 28829938 — intervention group
Group type: COMPARATOR
Intervention: Ketac Cem EasyMix (GIC, positive control)
Number of subjects: 70
Study 28829938 — intervention group
Group type: EXPERIMENTAL
Intervention: SeT
Number of subjects: 70
Study 28829938 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (Max)
Number of subjects: 70
Study 28829938 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Cem2 (Smart)
Number of subjects: 70
Study 28829938 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem 2 (Unicem2)
Number of subjects: 70
Study 25401456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic response ankle-foot orthoses (DR-AFO)
Number of subjects: 3
Study 25401456 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 3
Study 22520276 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Intervention (RMI)
Number of subjects: 100
Study 22520276 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 100
Study 21145848 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 200 mg q8 h
Number of subjects: 37
Study 21145848 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 200 mg q12 h
Number of subjects: 37
Study 21145848 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 300 mg q12 h (non-responders)
Number of subjects: 37
Study 21145848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19441869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours for 7-14 days
Number of subjects: 802
Study 19441869 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin 1 g every 12 hours with or without aztreonam 1 g every 8 hours)
Number of subjects: 802
Study 19441869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours for 5-14 days
Number of subjects: 802
Study 19441869 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g plus aztreonam 1 g every 12 hours
Number of subjects: 802
Study 19441869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 802
Study 16774462 — intervention group
Group type: EXPERIMENTAL
Intervention: All4You! intervention
Number of subjects: 988
Study 15612861 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Problem Solving (CPS)
Number of subjects: 47
Study 15612861 — intervention group
Group type: COMPARATOR
Intervention: Parent Training (PT)
Number of subjects: 47
Study 11747151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheath (HCS)
Number of subjects: 90
Study 11747151 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrophilic sheath (NHS)
Number of subjects: 90
Study 9360143 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone coated oxygenator (Mera Excelung Binding Prim HPO 15 H‐C)
Number of subjects: 16
Study 9360143 — intervention group
Group type: COMPARATOR
Intervention: Binding Prim HPO 25 H‐C (heparin coated oxygenator)
Number of subjects: 16
Study 7685588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (25,000 U/kg after induction of anesthesia, 25,000 U/kg added to the prime, 25,000 U/kg every hour of cardiopulmonary bypass)
Number of subjects: 48
Study 7685588 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without aprotinin)
Number of subjects: 48
Study 7685588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 48
Study 3573540 — intervention group
Group type: COMPARATOR
Intervention: 4.0 mEq/liter Ca dialysate
Number of subjects: 11
Study 3573540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 1,25(OH)2D3
Number of subjects: 11
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 110% Vmax
Number of subjects: 12
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 115% Vmax
Number of subjects: 12
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 120% Vmax
Number of subjects: 12
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 125% Vmax
Number of subjects: 12
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 130% Vmax
Number of subjects: 12
Study 28759534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 140% Vmax
Number of subjects: 12
Study 28063075 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐Solving Therapy for adherence and depression (PST‐AD)
Number of subjects: 32
Study 28063075 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (Control)
Number of subjects: 32
Study 27501119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 W/kg (low RF)
Number of subjects: 36
Study 27501119 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 W/kg (high RF)
Number of subjects: 36
Study 27501119 — intervention group
Group type: COMPARATOR
Intervention: 0 W/kg (sham)
Number of subjects: 36
Study 24421289 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol infusion (target BrAC = 0.06 g/dl)
Number of subjects: 295
Study 24421289 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 295
Study 23220322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 0
Study 23220322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Filling LC
Number of subjects: 0
Study 23220322 — intervention group
Group type: COMPARATOR
Intervention: Cavity Conditioner (20% polyacrylic acid)
Number of subjects: 0
Study 23220322 — intervention group
Group type: COMPARATOR
Intervention: Self Conditioner (no-rinse conditioner)
Number of subjects: 0
Study 23220322 — intervention group
Group type: COMPARATOR
Intervention: No conditioner
Number of subjects: 0
Study 21194607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 0.5 g
Number of subjects: 30
Study 21194607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g
Number of subjects: 30
Study 21194607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 2.0 g
Number of subjects: 30
Study 21194607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g BID for 7 days (multiple doses)
Number of subjects: 30
Study 21194607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium (all doses)
Number of subjects: 30
Study 16483699 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated dressing with Rifocort (camphorated parachlorophenol and iodoform)
Number of subjects: 40
Study 16483699 — intervention group
Group type: COMPARATOR
Intervention: Control group (merely sutured)
Number of subjects: 40
Study 16231622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 20
Study 12113323 — intervention group
Group type: EXPERIMENTAL
Intervention: Human synthetic secretin, mean dose 3.4 clinical units, administered intravenously every 4th week, on three occasions.
Number of subjects: 6
Study 12113323 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered intravenously every 4th week, on three occasions.
Number of subjects: 6
Study 10446103 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin concentrations in patients taking NSAIDs
Number of subjects: 312
Study 10446103 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin concentrations
Number of subjects: 312
Study 10446103 — intervention group
Group type: COMPARATOR
Intervention: Four day faecal excretion of (111)In labelled white cells
Number of subjects: 312
Study 7788039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg daily (divided into two doses) for 12 months
Number of subjects: 105
Study 7788039 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 105
Study 1977479 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone (IPS)
Number of subjects: 24
Study 1977479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 357233 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (300 mg)
Number of subjects: 40
Study 357233 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250 mg)
Number of subjects: 40
Study 30972808 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and emotional learning intervention
Number of subjects: 37
Study 30972808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 28910165 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 106
Study 25700100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6mg.kg(‐1) body mass)
Number of subjects: 10
Study 25700100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10
Study 24280464 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Number of subjects: 86
Study 24280464 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 86
Study 21682597 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency ureteroscopy (Group A)
Number of subjects: 271
Study 21682597 — intervention group
Group type: COMPARATOR
Intervention: Delayed ureteroscopy (Group B)
Number of subjects: 271
Study 19335924 — intervention group
Group type: EXPERIMENTAL
Intervention: Daidzein (DAI) and daidzein-7-O-beta-D-glucoside (DG) (1 mg DAI aglycone equivalents/kg body weight)
Number of subjects: 5
Study 16118096 — intervention group
Group type: EXPERIMENTAL
Intervention: SANS alone (Group 1)
Number of subjects: 43
Study 16118096 — intervention group
Group type: EXPERIMENTAL
Intervention: SANS combined with low-dose anticholinergic (5 mg oxybutynin hydrochloride) (Group 2)
Number of subjects: 43
Study 12097666 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (500 mL twice daily)
Number of subjects: 40
Study 12097666 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 40
Study 10401776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (adjustable to 100 or 25 mg)
Number of subjects: 178
Study 10401776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 178
Study 10401776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 8523357 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (pulsed electrical stimulation)
Number of subjects: 78
Study 8523357 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 78